Reducing the risk of death in patients with chronic kidney disease by 31% AstraZeneed has been a net breakthrough.

Dagledge was initially approved to control blood sugar levels in diabetics, but research in recent years has expanded the field of patients it benefits.
May, it was approved by the FDA as the first SGLT2 inhibitor to reduce the risk of cardiovascular death and hospitalization due to heart failure in patients with type 2 diabetes.
excellent results in Phase 3 clinical trials in patients with chronic kidney disease mean it is expected to be the first SGLT2 inhibitor to significantly improve survival benefits in patients with or without type 2 diabetes.
breakthrough promises to change the paradigm of treatment for chronic kidney disease, AstraZenecom said in a press release.
chronic kidney disease (CKD) is a serious ongoing disease affecting nearly 700 million people worldwide.
causes of CKD are diabetes, high blood pressure and ngnephritis.
the most severe cases (i.e., end-stage kidney disease, ESKD), decline in kidney function and kidney damage cause patients to need dialysis or kidney transplantation.
most CKD patients die of cardiovascular causes before reaching the end of kidney disease.
is a "first-in-class" oral SGLT2 inhibitor, a transport protein in the kidneys that assists in glucose re-absorption.
SGLT2 inhibitors reduce glucose levels in the blood by inhibiting the function of SGLT2 by allowing more glucose to be excreted from the urine.
last August, the FDA granted Dagrid net fast-track eligibility to slow progression in kidney failure and prevent cardiovascular disease and kidney failure in CKD patients.
in a randomized double-blind, placebo-controlled, international Phase 3 clinical trial called DAPA-CKD.
4,304 patients with grades 2-4 CKD and elevated levels of albumin excretion in their urine were treated with dagrids or placebos while receiving standard treatment.
the trial came from all over the world, with Asian patients accounting for 35 per cent.
CKD patients who participated in the trial, nearly 68 percent had type 2 diabetes at the same time.
end of the trial was a compound endpoint consisting of a significant decrease in renal function (defined as a continuous decline of more than 50% in the filtration rate of the cymdeal between the kidneys), and end-stage nephropathy, kidney death and cardiovascular death indicators.
results showed that Dagri net reduced the risk of this compound endpoint by 39%.
Photo Source: In a pre-booked subgroup analysis, Dagli net reduced the risk of primary endpoint by 36% in patients with type 2 diabetes, and by 50% in patients with CKD who were not associated with type 2 diabetes.
results show that Dagley net can also bring clinical benefits to CKD patients who do not have type 2 diabetes.
the progress of SGLT2 inhibitors in the treatment of chronic kidney disease has been significantly reduced in CKD patients with and without type 2 diabetes (Photo: Source: Reference) FDA-approved SGLT2 inhibitors include AstraZeneca's Dagled Net, Janssen's Kagle Net (cana) Gliflozin, product name Invokana), Lilly/Boehringer Ingelheim's Empagliflozin, product name Jardiance, and Pfizer/MSD's Ertugliflozin, product name Steglatro.
Kagligne was approved by the FDA last year to reduce the risk of end-of-life kidney disease (ESKD), decreased renal function, cardiovascular death and hospitalization due to heart failure in adult patients with diabetic nephropathy and type 2 diabetes.
in a Phase 3 clinical trial treating patients with heart failure, Engele net showed the effect of delaying the decline in renal function in exploratory clinical endpoints (see drug Mingkangde for details today).
Grigg Ingham and Lilly have launched Phase 3 clinical trials to further test Engele's net effect in patients with chronic kidney disease.
resources: s1, Farxiga means to never reduction in the risk of failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial. Retrieved August 30, 2020, from the farxiga showeded never reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial. Retrieved August 30, 2020, from.